SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Warlick Erica)
 

Search: WFRF:(Warlick Erica) > (2021) > Myeloablative Condi...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00010085naa a2201033 4500
001oai:DiVA.org:uu-441000
003SwePub
008210426s2021 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:146049185
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4410002 URI
0247 a https://doi.org/10.1016/j.bbmt.2020.09.0262 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1460491852 URI
040 a (SwePub)uud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Bejanyan, Nelliu H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA.4 aut
2451 0a Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index :b A Center for International Blood and Marrow Transplant Research Study
264 1b Elsevier,c 2021
338 a print2 rdacarrier
520 a Compared with reduced-intensity conditioning (RIC), myeloablative conditioning (MAC) is generally associated with lower relapse risk after allogeneic hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS). However, disease-specific risk factors in AML/MDS can further inform when MAC and RIC may yield differential outcomes. We analyzed HCT outcomes stratified by the Disease Risk Index (DRI) in 4387 adults (age 40 to 65 years) to identify the impact of conditioning intensity. In the low/ intermediate-risk DRI cohort, RIC was associated with lower nonrelapse mortality (NRM) (hazard ratio [HR],.74; 95% confidence interval [CI],.62 to.88; P <.001) but significantly greater relapse risk (HR, 1.54; 95% CI, 1.35 to 1.76; P <.001) and thus inferior disease-free survival (DFS) (HR, 1.19; 95% CI, 1.07 to 1.33; P =.001). In the high/ very high-risk DRI cohort, RIC was associated with marginally lower NRM (HR,.83; 95% CI,.68 to 1.00; P =.051) and significantly higher relapse risk (HR, 1.23; 95% CI, 1.08 to 1.41; P =.002), leading to similar DFS using either RIC or MAC. These data support MAC over RIC as the preferred conditioning intensity for patients with AML/MDS with low/intermediate-risk DRI, but with a similar benefit as RIC in high/very high-risk DRI. Novel MAC regimens with less toxicity could benefit all patients, but more potent antineoplastic approaches are needed for the high/ very-high risk DRI group.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng
653 a AML
653 a MDS
653 a DRI
653 a Myeloablative
653 a RIC
7001 a Zhang, Meijieu Med Coll Wisconsin, Div Biostat, Milwaukee, WI 53226 USA.4 aut
7001 a Bo-Subait, Khalidu Med Coll Wisconsin, Div Biostat, Milwaukee, WI 53226 USA.4 aut
7001 a Brunstein, Claudiou Univ Minnesota, Adult Blood & Marrow Transplant Program, Minneapolis, MN USA.4 aut
7001 a Wang, Hailinu Med Coll Wisconsin, Div Biostat, Milwaukee, WI 53226 USA.4 aut
7001 a Warlick, Erica D.u Univ Minnesota, Adult Blood & Marrow Transplant Program, Minneapolis, MN USA.4 aut
7001 a Giralt, Sergiou Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.4 aut
7001 a Nishihori, Taigau H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA.4 aut
7001 a Martino, Rodrigou Hosp Santa Creu & Sant Pau, Div Clin Hematol, Barcelona, Spain.4 aut
7001 a Passweg, Jakobu Univ Hosp Basel, Dept Internal Med, Div Hematol, Basel, Switzerland.4 aut
7001 a Dias, Ajoyu Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.4 aut
7001 a Copelan, Edwardu Atrium Hlth, Dept Hematol Oncol & Blood Disorders, Levine Canc Inst, Charlotte, NC USA.4 aut
7001 a Hale, Gregoryu Johns Hopkins All Childrens Hosp, Dept Hematol Oncol, St Petersburg, FL USA.4 aut
7001 a Gale, Robert Peteru Imperial Coll London, Haematol Res Ctr, Dept Immunol & Inflammat, London, England.4 aut
7001 a Solh, Melhemu Northside Hosp, Blood & Marrow Transplant Grp Georgia, Atlanta, GA USA.4 aut
7001 a Kharfan-Dabaja, Mohamed A.u Mayo Clin, Div Hematol Oncol, Blood & Marrow Transplantat Program, Jacksonville, FL USA.4 aut
7001 a Angel Diaz, Miguelu Hosp Infantil Univ Nino Jesus, Dept Hematol Oncol, Madrid, Spain.4 aut
7001 a Ganguly, Siddharthau Univ Kansas Hlth Syst, Div Hematol Malignancy & Cellular Therapeut, Kansas City, KS USA.4 aut
7001 a Gore, Stevenu Yale New Haven Med Ctr, Dept Internal Med, Sect Med Oncol, New Haven, CT USA.4 aut
7001 a Verdonck, Leo F.u Isala Clin, Dept Hematol Oncol, Zwolle, Netherlands.4 aut
7001 a Hossain, Nasheed M.u Loyola Univ Chicago, Stritch Sch Med, Dept Med, Stem Cell Transplant Program,Div Hematol Oncol, Maywood, IL USA.4 aut
7001 a Kekre, Natashau Ottawa Hosp, Dept Med, Blood & Marrow Transplant Program, Ottawa, ON, Canada.4 aut
7001 a Savani, Bipinu Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA.4 aut
7001 a Byrne, Michaelu Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol, Nashville, TN USA.4 aut
7001 a Kanakry, Christopheru NCI, Expt Transplantat & Immunol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.4 aut
7001 a Cairo, Mitchell S.u New York Med Coll, Dept Pediat, Div Pediat Hematol Oncol & Stem Cell Transplantat, New York, NY USA.,Dokkyo Med Univ, Dept Hematol & Oncol, Mibu, Tochigi, Japan.4 aut
7001 a Ciurea, Stefanu Univ Texas MD Anderson Canc Ctr, Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA.4 aut
7001 a Schouten, Harry C.u Acad Ziekenhuis, Dept Hematol, Maastricht, Netherlands.4 aut
7001 a Bredeson, Christopheru Ottawa Hosp, Dept Med, Blood & Marrow Transplant Program, Ottawa, ON, Canada.4 aut
7001 a Munker, Reinholdu Univ Kentucky, Sch Med, Div Med Oncol, Markey Canc Ctr, Lexington, KY 40536 USA.4 aut
7001 a Lazarus, Hillardu Case Western Reserve Univ, Dept Med, Univ Hosp Cleveland Med Ctr, Cleveland, OH 44106 USA.4 aut
7001 a Cahn, Jean-Yvesu CHU Grenoble Alpes, Dept Hematol, Grenoble, France.4 aut
7001 a van der Poel, Marjoleinu Maastricht Univ, Med Ctr, Dept Internal Med, Maastricht, Netherlands.4 aut
7001 a Rizzieri, Davidu Duke Univ, Div Hematol Malignancies & Cellular Therapy, Durham, NC USA.4 aut
7001 a Yared, Jean A.u Univ Maryland, Dept Med, Greenebaum Comprehens Canc Ctr, Blood & Marrow Transplantat Program,Div Hematol O, Baltimore, MD 21201 USA.4 aut
7001 a Freytes, Cesaru Texas Transplant Inst, Hematopoiet Stem Cell Transplant Program, San Antonio, TX USA.4 aut
7001 a Cerny, Janu Univ Massachusetts, Med Ctr, Dept Med, Div Hematol Oncol, Worcester, MA USA.4 aut
7001 a Aljurf, Mahmoudu King Faisal Specialist Hosp Ctr & Res, Dept Oncol, Riyadh, Saudi Arabia.4 aut
7001 a Palmisiano, Neil D.u Thomas Jefferson Univ, Sidney Kimmel Canc Ctr, Philadelphia, PA 19107 USA.4 aut
7001 a Pawarode, Attapholu Univ Michigan, Sch Med, Dept Internal Med, Div Hematol Oncol,Blood & Marrow Transplantat Pro, Ann Arbor, MI USA.4 aut
7001 a Bacher, Vera Ulrikeu Univ Bern, Bern Univ Hosp, Dept Hematol, Inselspital, Bern, Switzerland.4 aut
7001 a Grunwald, Michael R.u Atrium Hlth, Dept Hematol Oncol & Blood Disorders, Levine Canc Inst, Charlotte, NC USA.4 aut
7001 a Nathan, Sunitau Rush Med Coll, Dept Internal Med, Div Hematol Oncol & Cell Therapy, Sect Bone Marrow Transplantat & Cellular Therapy, Chicago, IL 60612 USA.4 aut
7001 a Wirk, Baldeepu Penn State Canc Inst, Bone Marrow Transplant Program, Hershey, PA USA.4 aut
7001 a Hildebrandt, Gerhard C.u Univ Kentucky, Sch Med, Div Med Oncol, Markey Canc Ctr, Lexington, KY 40536 USA.4 aut
7001 a Seo, Sachikou Dokkyo Med Univ, Dept Hematol & Oncol, Mibu, Tochigi, Japan.,NHLBI, Lab Myeloid Malignancies, NIH, Bldg 10, Bethesda, MD 20892 USA.4 aut
7001 a Olsson, Richardu Uppsala universitet,Centrum för klinisk forskning i Sörmland (CKFD),Karolinska Inst, Dept Lab Med, Stockholm, Sweden.4 aut0 (Swepub:uu)riols677
7001 a George, Bijuu Christian Med Coll & Hosp, Dept Haematol, Vellore, Tamil Nadu, India.4 aut
7001 a de Lima, Marcosu Univ Hosp Case Med Ctr, Seidman Canc Ctr, Dept Med, Cleveland, OH USA.4 aut
7001 a Hourigan, Christopher S.u NHLBI, Lab Myeloid Malignancies, NIH, Bldg 10, Bethesda, MD 20892 USA.4 aut
7001 a Sandmaier, Brenda M.u Univ Washington, Div Med Oncol, Seattle, WA 98195 USA.;Fred Hutchinson Canc Res Ctr, Clin Res Div, 1124 Columbia St, Seattle, WA 98104 USA.4 aut
7001 a Litzow, Marku Mayo Clin, Div Hematol, Rochester, MN USA.4 aut
7001 a Kebriaei, Partowu Univ Texas MD Anderson Canc Ctr, Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA.4 aut
7001 a Saber, Waelu Med Coll Wisconsin, Div Biostat, Milwaukee, WI 53226 USA.4 aut
7001 a Weisdorf, Danielu Univ Minnesota, Dept Med, Div Hematol Oncol & Transplantat, Box 736 UMHC, Minneapolis, MN 55455 USA.4 aut
7102 a H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplant & Cellular Immunot, Tampa, FL USA.b Med Coll Wisconsin, Div Biostat, Milwaukee, WI 53226 USA.4 org
7730 t Transplantation and Cellular Therapyd : Elsevierg 27:1, s. 68.e1-68.e9q 27:1<68.e1-68.e9x 2666-6375x 2666-6367
8564 u https://doi.org/10.1016/j.bbmt.2020.09.026
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-441000
8564 8u https://doi.org/10.1016/j.bbmt.2020.09.026
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:146049185

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view